The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical ...

Thu, January 5, 2012 at 2:30 PM UTC ImmunoCard C. difficile GDH is geared to detect a common antigen, known as Glutamate dehydrogenase (“GHD”), produced by the toxigenic and non-toxigenic forms of C.

Diagnostics company Meridian Bioscience (NASDAQ:VIVO) plans to launch a new C. difficile test in Europe. C. difficile is a bacterium that can cause symptoms ranging from diarrhea to life-threatening ...

Meridian Bioscience Inc. (NASDAQ: VIVO), the Cincinnati, Ohio diagnostic test maker, has received FDA clearance for its new Clostridium difficile test. The ImmunoCard C. difficile GDH test has already ...

The presence of antigen-specific and neutralizing antibodies was not associated with Clostridioides difficile infection symptoms, severity, therapy approach, treatment response, or recurrences in a ...

There are trillions of bacteria that live in your colon. Most of them are harmless and many are actually helpful, supporting digestion and keeping your immune system strong. C. diff is one type of ...

C. diff is a type of bacteria that can cause diarrhea, abdominal pain, and tenderness. It is commonly treated with antibiotics such as fidaxomicin (Dificid) and vancomycin (Firvanq). C. diff, short ...

Clostridium difficile infection is the leading cause of gastroenteritis-associated death and has become the most common cause of health care–associated infections in US hospitals. For long-term care ...

CINCINNATI--(BUSINESS WIRE)--Meridian Bioscience, Inc. (NASDAQ:VIVO) is pleased to announce the launch of a new Clostridium difficile rapid test, ImmunoCard C. difficile GDH. This assay detects the ...